Search Result

Results for "

FLT3/D835Y

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FLT3 (22) Apoptosis (4) Aurora Kinase (1) Bcr-Abl (1) Checkpoint Kinase (Chk) (1) Cytochrome P450 (1) FAK (1) JAK (3)
By Research Areas:	Cancer (22)

Targets Recommended: FLT3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112145

FLT3-IN-3

1 Publications Verification

FLT3 Cancer

FLT3-IN-3 is a potent FLT3 inhibitor with IC₅₀s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.

FLT3-IN-3 1 Publications Verification	FLT3	Cancer
FLT3-IN-3 is a potent *FLT3* inhibitor with IC₅₀s of 13 and 8 nM for FLT3 WT and **FLT3 D835Y**, respectively.

HY-143434

FLT3/D835Y-IN-1	FLT3	Cancer
FLT3/D835Y-IN-1 (compound 13a) is a orally active, potent and selective *FLT3* and *FLT3/D835Y* inhibitor, with IC₅₀ values of 0.26 nM and 0.18 nM, respectively. FLT3/D835Y-IN-1 also blocks tumor growth, has anticancer efficacy, and can be used to research for AML (acute myeloid leukemia) .

HY-161323

FLT3-ITD/D835Y-IN-1	FLT3 Bcr-Abl Apoptosis	Cancer
FLT3-ITD/D835Y-IN-1 (Compound 1) is a *FLT3-ITD* and BCR-ABL inhibitor. FLT3-ITD/D835Y-IN-1 mediates proapoptosis by inhibiting the FLT3 and BCR-ABL pathways, as well as other possible targets. FLT3-ITD/D835Y-IN-1 can be used in the study of acute myeloid leukemia (AML) .

HY-155302

FLT3-IN-22	FLT3	Cancer
FLT3-IN-22 (compound 22f) is a potent *FLT3* inhibitor with IC₅₀ values of 0.941 nM and 0.199 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-22 exhibits strong antiproliferative activity against MV4-11 cells and the mutant FLT kinase expressed Ba/F3 cell lines, including FLT-D835Y and FLT3-F691L .

HY-146886

FLT3-IN-15	FLT3	Cancer
FLT3-IN-15 is a highly potent and orally active *FLT3* inhibitor with IC₅₀s of 0.87 nM and 0.32 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-15 can be used for researching acute myeloid leukemia .

HY-155770

FLT3-IN-20	FLT3	Cancer
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor with IC₅₀ values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-20 has anti-proliferation efficacy in FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM, respectively) and the MOLM-13 variant (4 nM) with the FLT3-ITD-D835Y mutation. FLT3-IN-20 can be used in research of cancer .

HY-18161

CCT241736	FLT3 Aurora Kinase	Cancer
CCT241736 is a potent and orally bioavailable dual *FLT3* and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).

HY-162032

FLT3-IN-25	FLT3	Cancer
FLT3-IN-25 (compound 17) is a potent inhibitor of *FLT3, with IC₅₀s of 1.2 nM, 1.4 nM and 1.1 nM for FLT3-WT, FLT3-D835Y and FLT3-ITD, respectively. FLT3*-IN-25 plays an important role in acute myeloid leukemia (AML) .

HY-12333

Denfivontinib G-749	FLT3 Apoptosis	Cancer
Denfivontinib (G-749) is a potent, oral active and ATP competitive *FLT3* inhibitor, with IC₅₀s of 0.4 nM and 0.6 nM for FLT3 wild type and FLT3-D835Y, respectively. Denfivontinib can be used for the research of agent resistance for acute myeloid leukemia (AML) .

HY-148070

FLT3-IN-17	FLT3 FAK Cytochrome P450	Cancer
FLT3-IN-17 inhibits CYPs and *FLT3* mutants activity (IC₅₀s: <0.5 nM for D835Y). FLT3-IN-17 is also a FAK inhibitor, with an IC₅₀ value of 12 nM. FLT3 ligand-2 can be used in the research of cancers .

HY-143895

FLT3-IN-12	FLT3	Cancer
FLT3-IN-12 is a potent, selective and orally active FLT3 kinase inhibitor with IC₅₀s of 1.48 nM and 2.87 nM for *FLT3-WT* and *FLT3-D835Y, respectively. FLT3-IN-12 possesses high selectivity over c-KIT (>1000-fold). FLT3-IN-12 has an excellent anti-AML (acute myeloid leukemia) activity (MV4-11, IC₅₀* of 0.75 nM) .

HY-18949

JI6
JI6 is a potent, selective and orally active *FLT3* inhibitor, with IC₅₀s of ∼40, 8, and 4 nM for *FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits JAK3* and c-Kit, with IC₅₀s of ∼250 and ∼500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia .

HY-143894

FLT3-IN-11	FLT3	Cancer
FLT3-IN-11 (compound 30) is a potent, selective and orally active FLT3 kinase inhibitor with IC₅₀s of 7.22 nM and 4.95 nM for wild-type FLT3 and *FLT3-D835Y, respectively. FLT3-IN-11 high selectivity for FLT3* over c-KIT (>1000-fold). FLT3-IN-11has excellent anti-acute myeloid leukemia (AML) activity (MV4-11 cells, IC₅₀ of 3.2 nM) .

HY-153857

PHI-101	FLT3	Cancer
PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations. PHI-101 potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. PHI-101 has potential for research in relapsed or refractory acute myeloid leukemia (AML) .

HY-155594

LT-540-717	FLT3	Cancer
LT-540-717 (compound 32) is a potent FLT3 inhibitor (IC₅₀=0.62 nM) with antiproliferative activity. LT-540-717 also inhibits several acquired FLT3 mutations, FLT3 (ITD, D835V), FLT3 (ITD, F691L), FLT3 (D835Y) and FLT3 (D835V). LT-540-717 has potential to be an anti-AML agent .

HY-144710

FLT3/ITD-IN-2	FLT3	Cancer
FLT3/ITD-IN-2 (Compound 17) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 1.0 nM against FLT3 ^D835Y, *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-2 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-144711

FLT3/ITD-IN-3	FLT3	Cancer
FLT3/ITD-IN-3 (Compound 19) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 0.9 nM against FLT3 ^D835Y, *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-3 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-16379

Pacritinib Maximum Cited Publications 13 Publications Verification SB1518	JAK FLT3	Cancer
Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits *FLT3* (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

HY-162367

FLT3/CHK1-IN-2	FLT3 Checkpoint Kinase (Chk)	Cancer
FLT3/CHK1-IN-2 (Compound 30) is a dual inhibitor of *FLT3* and CHK1, with IC₅₀s of 25.63, 16.39, 22.80 nM for CHK1, FLT3-WT, and FLT-D835Y respectively. FLT3/CHK1-IN-2 has favorable oral PK properties and kinase selectivity. FLT3/CHK1-IN-2 can be used for research of acute myeloid leukemia (AML) .

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective *FLT3* inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells ^[3].

HY-145015A

Tuspetinib hydrate HM43239 hydrate	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) hydrate is an orally active and selective *FLT3* inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib hydrate inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib hydrate inhibits the proliferation and induces the apoptosis of leukemic cells ^[3].

HY-16379A

Pacritinib hydrochloride SB1518 hydrochloride	JAK FLT3	Cancer
Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib hydrochloride also inhibits *FLT3* (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) ^[3].

HY-16379B

Pacritinib citrate SB1518 citrate	JAK FLT3	Cancer
Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib citrate also inhibits *FLT3* (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) ^[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

FLT3/D835Y

Inhibitors & Agonists